THM Capital Advisory advises WOMED on its €6 million Series A

THM Capital Advisory supports WOMED in its €6 million Series A to launch Womed Leaf™ and accelerate its portfolio of intrauterine therapies.

WOMED announces a fundraising of 6 million euros in Series A, financed by private investors and the French fund IRDI, with THM Capital Advisory as the sole financial advisor for the operation.

WOMED is a Femtech startup that develops innovative, safe and effective treatments to help fight infertility and complex uterine pathologies.

The company was founded by the healthtech entrepreneur Gonzague Issenmann, Professor Xavier Garric, a specialist in biomedical polymers, and Dr. Stephanie Huberlant, a reproductive specialist, in order to commercialize an invention from the laboratory.”Polymers for Health and Biomaterials” from the University of Montpellier (France).

This proprietary technology forms the basis of a platform dedicated to intrauterine solutions, designed to directly target the uterine cavity, where the pathology is localized.

The first product, Womed Leaf™, is a medical device intended to treat and prevent uterine wall attachment after surgery (intrauterine adhesions), a complication that may be responsible for infertility and obstetric complications such as abnormal placentation.

Womed Leaf™ has obtained the CE mark in accordance with the new European regulations, and clinical trial effectiveness data is due to be presented in the first half of 2024.

Beyond Leaf™, WOMED is developing intrauterine drug delivery therapies for the treatment of fibroids, endometriosis and acute bleeding, which affect hundreds of millions of women around the world.

The purpose of Series A is to fund the commercial launch of Leaf™ and the continued development of this portfolio of proprietary intrauterine therapies.

THM Capital Advisory supported the founders of WOMED as financial advisor, with a team composed of Thomas Mitard, Juan Fernando Ramirez, Aurélien Prost and Paul Demorge, alongside Villechenon (Morgan Hunault-Berret, Quentin Dupont) as legal advisor.

Investors were advised on IP & legal aspects by LPA-CGR Avocats (Mathieu Selva, Stéphane Erard), as well as by White & Case (Alexandre Ippolito, Baptiste Ferraud) and Raion (Claire Feller).